Lee Tien-Li
Known title: Chief Executive OfficerCIK: 0001940120
Lee Tien-Li's purchase track record
How the stock did after each of Lee Tien-Li's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since February 14, 2025
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-35.0%
3 months: -25.6%
Beat the S&P 500
0%
median -38.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/11/2025 | AARD | $101K | -66.3% | -76.7% | +7.1% |
| 9/10/2025 | AARD | $257K | +74.8% | -35.0% | +3.7% |
| 2/14/2025 | AARD | $265K | -25.6% | -18.9% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AARD | ▲ Buy | Open Market | 7,000 | $101K | 12/11/2025 | View on chart |
| AARD | ▲ Buy | Option Exercise | 1,229 | $5K | 10/15/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 3,500 | $35K | 9/15/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 6,500 | $62K | 9/15/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 5,000 | $43K | 9/12/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 6,000 | $47K | 9/11/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 9,000 | $71K | 9/10/2025 | View on chart |
| AARD | ▲ Buy | Option Exercise | 17,209 | $73K | 8/28/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 16,542 | $265K | 2/14/2025 | View on chart |
| AARD | ▼ Sell | Other | 41,303 | — | 2/14/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD)
RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.